Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal and age-related interstitial lung disease whose etiology and pathogenesis are still largely unknown. It is important to identify IPF patients at high risk of mortality so that early appropriate treatment can improve their prognosis. Therefore, the investigation of available and reliable prognostic biomarkers for IPF is crucial.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Pathophysiological mechanisms and therapeutic perspectives
Metabolic syndrome in patients with schizophrenia
- Hand eczema: from diagnosis to treatment
Implementing sustainable, stage-appropriate measures
- Cystic fibrosis
Small spray – big footprint
- From symptom to diagnosis
Abdominal pain – Gastric outlet stenosis
- When the bones become more fragile: “Case Finding”
Fracture risk reduction in osteoporosis
- Biologics for plaque psoriasis
What increases the chance of a sustained remission?
- Pain and autism
Hurdles to pain treatment for autistic patients
- Findings from the ALS Symposium 2024 in Montreal